WAYNE, PA — Teleflex Incorporated (NYSE: TFX), a key player in the medical device industry, announced this week the full market release of its groundbreaking Advanced Tissue Control (ATC) feature for the UroLift™ 2 System. This enhancement is poised to transform the treatment of benign prostatic hyperplasia (BPH), offering new levels of precision and effectiveness for men with prostate sizes up to 100g. The UroLift™ 2 System with ATC has secured FDA clearance, reinforcing its position as a leader in minimally invasive BPH treatments.
BPH, commonly known as an enlarged prostate, affects millions of men worldwide, leading to significant urinary symptoms that can impact quality of life. Traditional treatments have ranged from medication to major surgery, each with its own set of challenges and side effects. The UroLift™ 2 System emerged as a minimally invasive alternative, renowned for its ability to relieve symptoms without the complications associated with more invasive procedures.
The introduction of the ATC feature represents a leap forward in BPH care. Designed based on extensive physician feedback, the UroLift™ 2 ATC offers customizable treatments tailored to the unique anatomical needs of each patient. This personalization aims to maximize treatment effectiveness while ensuring patient comfort and safety.
Key innovations of the UroLift™ 2 ATC include tissue control wings and laser-etched needle markers that enhance the precision of tissue manipulation and implant delivery. These features, combined with a streamlined delivery system, offer physicians improved control and accuracy during procedures. The result is a more efficient treatment process, with one handle per procedure and individual implant cartridges reducing both waste and procedural complexity.
Jake Newman, President of The Americas at Teleflex, highlighted the system’s comprehensive approach to BPH care, noting, “UroLift™ 2 ATC optimizes enlarged prostate treatment by providing urologists with unparalleled confidence and customization capabilities.” This sentiment was echoed by Brian Wilkins, Vice President of Research and Development for Teleflex Interventional Urology, who pointed out the system’s ability to treat a broader range of patients efficiently.
Physicians already using the UroLift™ 2 ATC have praised its transformative impact on BPH care. Dr. Adam Craig Thomas of Parkview Physicians Group Urology in Fort Wayne, Indiana, described it as a “game-changer,” while Dr. Mark Pe of Genesis Urology in San Diego, California, emphasized its utility in treating diverse patient anatomies.
The launch of the UroLift™ 2 ATC by Teleflex marks a significant advancement in the field of urology, offering a promising new option for men suffering from BPH. By combining proven clinical outcomes with innovative technology, the UroLift™ 2 System with ATC sets a new standard in the treatment of this common condition, potentially improving the lives of millions of men around the globe.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.